Leerink Partnrs downgraded shares of 2seventy bio (NASDAQ:TSVT – Free Report) from a strong-buy rating to a hold rating in a report released on Tuesday morning,Zacks.com reports.
Other research analysts also recently issued research reports about the stock. Leerink Partners reissued a “market perform” rating and set a $5.00 price objective (down previously from $9.00) on shares of 2seventy bio in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of 2seventy bio in a research report on Friday, March 7th. One analyst has rated the stock with a sell rating, four have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $6.83.
Read Our Latest Stock Report on 2seventy bio
2seventy bio Price Performance
Institutional Trading of 2seventy bio
Several institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its stake in 2seventy bio by 317.1% in the fourth quarter. Bank of America Corp DE now owns 2,515,897 shares of the company’s stock worth $7,397,000 after purchasing an additional 1,912,771 shares during the last quarter. Regeneron Pharmaceuticals Inc. bought a new stake in 2seventy bio in the fourth quarter worth about $3,689,000. Geode Capital Management LLC lifted its stake in 2seventy bio by 1.1% in the third quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock worth $5,553,000 after purchasing an additional 13,144 shares during the last quarter. State Street Corp raised its stake in shares of 2seventy bio by 1.5% during the third quarter. State Street Corp now owns 1,058,773 shares of the company’s stock valued at $4,997,000 after acquiring an additional 15,638 shares in the last quarter. Finally, Eversept Partners LP raised its stake in shares of 2seventy bio by 0.6% during the fourth quarter. Eversept Partners LP now owns 1,003,678 shares of the company’s stock valued at $2,951,000 after acquiring an additional 5,599 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.
2seventy bio Company Profile
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
Recommended Stories
- Five stocks we like better than 2seventy bio
- The How and Why of Investing in Gold Stocks
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- Insider Selling Explained: Can it Inform Your Investing Choices?
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- What is diluted earnings per share (Diluted EPS)?
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.